Your browser doesn't support javascript.
loading
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - single hospital experience.
Sivina, Elina; Blumberga, Lubova; Purkalne, Gunta; Irmejs, Arvids.
Afiliación
  • Sivina E; Institute of Oncology, Tumour Clinical Research Department, Riga Stradins University, Riga, Latvia. elinasivina@inbox.lv.
  • Blumberga L; Clinic of Oncology, Pauls Stradins Clinical University Hospital, Riga, Latvia. elinasivina@inbox.lv.
  • Purkalne G; Department of Internal Diseases, Riga Stradins University, Riga, Latvia. elinasivina@inbox.lv.
  • Irmejs A; Clinic of Oncology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Hered Cancer Clin Pract ; 21(1): 4, 2023 Mar 16.
Article en En | MEDLINE | ID: mdl-36922883
BACKGROUND: Triple-negative breast cancer is a heterogeneous molecular subtype of BC. Pathological complete response (pCR) is an important surrogate marker for recurrence-free and overall survival. AIM OF STUDY: The aim of this study was to evaluate clinical and pathological factors that are associated with complete pathological response status in triple-negative breast cancer patients receiving neoadjuvant chemotherapy. MATERIALS AND METHODS: Eighty triple-negative breast cancer patients who underwent neoadjuvant chemotherapy followed by surgery at Pauls Stradins Clinical University Hospital between January 2018 and January 2020 were retrospectively analysed. Twenty-six patients (32.5%) were BRCA1/2 pathogenic variant carriers. RESULTS: A total of 32.5% (n = 26) of patients in all study groups and 57.7% (n = 15) of patients with BRCA1/2 pathogenic variants achieved pCR. Forty-seven patients received platinum-based neoadjuvant chemotherapy, and 19 patients (40.4%) achieved complete pathological response. Patients in the pCR group presented with significantly higher Ki-67 scores (p = 0.007), BRCA1/2 pathogenic variants (p = 0.001) and younger age (p = 0.02) than those in the non-pCR group. pCR did not significantly impact recurrence-free survival (RFS) or overall survival (OS). Multivariate analysis revealed that pretreatment N stage (clinical nodal status) was an independent prognostic factor for RFS and OS. CONCLUSIONS: BRCA1 pathogenic variants, high Ki67 score and young age were predictors of pathological complete response, while clinical nodal status predicted survival outcomes in triple-negative breast cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Hered Cancer Clin Pract Año: 2023 Tipo del documento: Article País de afiliación: Letonia Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Hered Cancer Clin Pract Año: 2023 Tipo del documento: Article País de afiliación: Letonia Pais de publicación: Polonia